---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037737"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2026-08-13T20:02:19+00:00"
generated_at: "2026-08-13T20:03:18.925638+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Daré launches first product Flora Sync LF5, Q2 revenue $0.2M, positive Ovaprene data

## Summary
- Launched Flora Sync LF5, first directly commercialized product; revenue began in July 2026.
- Q2 2026 total revenue $0.2M vs $(0.02)M YoY; cost of revenues $0.3M.
- Cash and equivalents ~$12.6M; working capital deficit ~$0.2M.
- Positive interim Phase 3 Ovaprene results; DSMB recommends continue without modification.
- DARE to PLAY Sildenafil Cream on track for Q3 2026 dispensing and revenue; prescriptions accepted.

## SEC filing metadata
- accession: 0001493152-26-037737
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2026-08-13T20:02:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/0001493152-26-037737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037737
- JSON: https://secwatch.observer/filing/0001493152-26-037737.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.